Biomarin has granted Ascendis a non-exclusive, worldwide license to use navepegritide, the active ingredient in the latter company’s recently approved achondroplasia drug Yuviwel, in exchange for 18–20% royalties on net sales.

Original title: “Biomarin nabs big royalties in achondroplasia patent settlement with Ascendis”

At a big meeting for cardiovascular medicines, Cytokinetics and Arrowhead aimed to separate their drugs from competitors while a failed study pressured Alnylam.

Original title: “ESC ‘26: Cytokinetics’ sell-off, Arrowhead’s edge and a heart drug autopsy”

What's possible when AI models can learn from additional health data modalities to create a more complete understanding of human health?

Original title: “The next frontier: Advancing foundation models with multimodal data”

The U.S. is scrambling to compete with a strategically positioned China on the biotech stage as the Asian country surpasses America in biomedical research and clinical trials. So far, China is winning.

Original title: “China poses increasing security risk as US biotech innovation edge erodes”

Moderna’s upsized note offering quickly followed a big win in a crucial study. Elsewhere, a biotech’s shares tumbled after study data were “inadvertently” published ahead of a medical meeting.

Original title: “Moderna raises $2.6B to support cancer work; FDA clears updated COVID vaccines”

Teva Pharmaceuticals is the 'stalking horse bidder' to kick off the auction process for BioXcel Therapeutics' AI-derived assets as the biotech files for Chapter 11 bankruptcy.

Original title: “BioXcel files for bankruptcy, will sell assets to Teva for up to $125M”

Not only is the XBI continuing to hover around a historic high, but drug companies can’t seem to get enough of both large IPOs and big-ticket M&A.

Original title: “This week in charts: Biotech’s rebound is undeniable”

Through its DualityBio deal, Roche's Genentech hopes to create antibody-drug conjugates with payloads that can circumvent growing cancer drug resistance.

Original title: “Genentech strikes second Asia deal in a week, betting up to $1B in oncology ADC alliance with DualityBio”

Manufacturers are being pushed beyond mAb‑era platforms into a new design model built around molecular engineering, complex analytics and amplified upstream and downstream processing.

Original title: “Multispecifics are transforming the CDMO development architecture”

Though its data could be useful for pharmaceutical firms, Polansky’s latest entrepreneurial endeavor, Outer Bio, is serious about steering clear of road bumps that slow biotechs.

Original title: “Michael Polansky has a new, skin-focused biotech. Don’t call it a drug company.”

Rasonque’s $39,800 monthly list price surpassed Wall Street forecasts and led to rosier sales projections ahead of what one analyst described as a “historic” launch.

Original title: “Revolution pancreatic cancer drug should quickly become a blockbuster, analysts say”